Why the study?
Does prazosin improve haemodynamics and clinical status in patients with severe chronic congestive cardiac failure?
Does prazosin improve haemodynamics and clinical status in patients with severe chronic congestive cardiac failure?
Prazosin provides acute haemodynamic benefits in severe chronic congestive heart failure but does not consistently provide long-term clinical improvement.
Answers are grounded in this paper and cite their sources.
Acute hemodynamic effects of prazosin in severe CHF are hypothesis-generating; long-term clinical benefit remains unproven.
The acute haemodynamic effects of prazosin 5 mg were investigated in 11 patients with severe chronic congestive cardiac failure. Six patients had their antifailure therapy discontinued while five continued on their usual medication. Two patients were exercised before and after prozosin. Following the drug, pulmonary capilary wedge pressure diminished 7 +/- 2(SE) mmHg (P < 0.005) and cardiac index increased 17 +/- 6% (P < 0.02). Mean arterial pressure fell in all subjects (- 9 +/- 2 mmHg; P < 0.001) and systemic vascular resistance was reduced in all but one (- 19 +/- 5%; P < 0.005). There was no significant change in heart rate. Four of the five subjects whose regular medications were continued were evaluated by clinical examination, chest X-ray, echocardiogram and treadmill stress test, before and after four weeks of prazosin therapy, one subject having died in this time. Two improved, one deteriorated and one remained unchanged. Thus, chronic prazosin therapy benefited individual patients but did not consistently provide long term improvement.
No takes yet. Share an insight, caveat, or question.
Hockings et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: